- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06071702
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Brenda Koltun Reuven
- Phone Number: +972542666688
- Email: brendak@medinol.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Patient with an indication for PCI including NSTEMI (biomarkers have peaked or are falling), angina (stable or unstable), silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80, Pd/Pa≤0.91or iFR, RFR, DFR, DPR≤0.89 must be present).
- Non-target vessel PCIs are allowed if performed >30 days prior to index procedure.
- Patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule.
- Staged procedures are allowed as long as the IoNIR stent is implanted in the last procedure and at least 30 days have elapsed between the previous procedure and the IoNIR PCI.
- A maximum of two vessels and up to two lesions may be treated (two lesions separated by up to 10mm that can be covered by a single stent are considered as one lesion).
- Lesions requiring scoring/cutting and/or rotational/orbital atherectomy and/or intra-vascular lithotripsy are allowed.
- Overlapping stents are allowed.
- Target lesion must be in a major native coronary artery with visually estimated diameter of ≥2.5 mm to ≤4.0 mm and lesion length of up to 40 mm, and appropriate size IoNIR stents are available.
Exclusion Criteria:
1. ST Segment Elevation MI within past 30 days. 2. NSTEMI with biomarkers that have not peaked. 3. Significant valvular disease or planned valvular intervention. 4. PCI within the 30 days preceding the baseline procedure. 5. PCI in the target vessel within 12 months of the baseline procedure. 6. Planned staged procedures (coronary or valvular), where the study stent is implanted in the first stage.
7. Brachytherapy in conjunction with the baseline procedure. 8. Known history of stent thrombosis. 9. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure <90 mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support, including IABP.
10. Subject is intubated. 11. Known LVEF <30%. 12. Contraindication to DAPT for 6 months in non-ACS patients and 12 months in ACS patients (including planned surgeries that cannot be delayed).
13. Subject has an indication such as atrial fibrillation for oral anticoagulation/prolonged heparinization (i.e., use of coumadin/DOAC (NOAC) or prolonged enoxaparin/heparin therapy is not allowed).
14. eGFR <60 mL/min. 15. Hemoglobin <10 g/dL. 16. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3. 17. White blood cell (WBC) count <3,000 cells/mm3. 18. Clinically significant liver disease. 19. Active peptic ulcer or active bleeding from any site. 20. Bleeding from any site within the previous 8 weeks requiring active medical or surgical attention.
21. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath.
22. History of bleeding diathesis or coagulopathy and patients that refuse blood transfusions.
23. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any permanent neurologic defect attributed to CVA.
24. Known allergy to the study stent components (cobalt, nickel, chromium, molybdenum, platinum, PDLG, PLC, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus, everolimus, or similar drugs or any other analogue or derivative or similar compounds).
25. Known allergy to protocol-required concomitant medications such as aspirin, or P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor), heparin and bivalirudin, or iodinated contrast allergy that cannot be adequately pre-medicated.
26. Any co-morbid condition that may cause non-compliance with the protocol (e.g., dementia, substance abuse, etc.) or reduced life expectancy to <24 months (e.g., cancer, severe heart failure, severe lung disease).
27. Patient is participating in or plans to participate in any other investigational drug or device clinical trial that has not reached its primary endpoint.
28. Women who are pregnant or breastfeeding. 29. Women who intend to become pregnant within 12 months after the baseline procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the baseline procedure).
30. Patient has received an organ transplant or is on a waiting list for an organ transplant.
31. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the baseline procedure.
32. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are allowed.
33. Complex lesions including severely calcified lesions, presence of visible thrombus, chronic total occlusions, bifurcation lesions (side branch diameter ≥2.0 mm), tortuous lesions, restenotic lesions, left main lesions, ectasia, aneurysm and any bypass graft lesions.
34. Another lesion in a target or non-target vessel (including all side branches) is present that requires or has a high probability of requiring PCI within 12 months after the baseline procedure.
35. Ostial lesions within 3 mm of origin of LAD, LCx, lesions in the LM.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IoNIR Ridaforolimus-Eluting Coronary Stent
IoNIR Ridaforolimus-Eluting Coronary Stent System
|
The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-stent Late Loss (LL)
Time Frame: 13 months
|
In-stent Late Loss (LL) at 13 months assessed by quantitative coronary angiography (QCA) (Minimal Lumen Diameter (MLD) post-procedure - MLD follow-up (US patients only))
|
13 months
|
Target Lesion Failure
Time Frame: 1 year
|
Target Lesion Failure (composite of cardiovascular death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization)
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiac events
Time Frame: 30 days, 6 months, 1,2,3,4,5 years
|
Major adverse cardiac events (MACE; the composite rate of cardiovascular death, any MI or ischemia-driven target lesion revascularization (TLR)).
|
30 days, 6 months, 1,2,3,4,5 years
|
All-cause mortality
Time Frame: 30 days, 6 months, 1,2,3,4,5 years
|
All-cause mortality
|
30 days, 6 months, 1,2,3,4,5 years
|
Cardiovascular death
Time Frame: 30 days, 6 months, 1,2,3,4,5 years
|
Cardiovascular death
|
30 days, 6 months, 1,2,3,4,5 years
|
Myocardial infarction
Time Frame: 30 days, 6 months, 1,2,3,4,5 years
|
Myocardial infarction
|
30 days, 6 months, 1,2,3,4,5 years
|
Target vessel related MI
Time Frame: 30 days, 6 months, 1,2,3,4,5 years
|
Target vessel related MI
|
30 days, 6 months, 1,2,3,4,5 years
|
Target Lesion Failure
Time Frame: 6 months, 2, 3, 4, 5 years
|
Target Lesion Failure
|
6 months, 2, 3, 4, 5 years
|
Ischemia-driven TLR
Time Frame: 30 days, 6 months, 1, 2, 3, 4, 5 years
|
Ischemia-driven TLR
|
30 days, 6 months, 1, 2, 3, 4, 5 years
|
Ischemia-driven Target Vessel Revascularization
Time Frame: 30 days, 6 months, 1, 2, 3, 4, 5 years
|
Ischemia-driven Target Vessel Revascularization
|
30 days, 6 months, 1, 2, 3, 4, 5 years
|
Stent thrombosis
Time Frame: 30 days, 6 months, 1, 2, 3, 4, 5 years
|
Stent thrombosis (ARC-2 definite and probable).
|
30 days, 6 months, 1, 2, 3, 4, 5 years
|
Acute Device Success
Time Frame: index procedure
|
Acute Device Success (successful crossing and deployment with residual QCA DS <30%)
|
index procedure
|
Luminal gain
Time Frame: 13 months - US patients only
|
Luminal gain (MLD post-procedure - MLD pre-procedure)
|
13 months - US patients only
|
In-stent MLD
Time Frame: 13 months - US patients only
|
In-stent MLD
|
13 months - US patients only
|
In-segment MLD
Time Frame: 13 months - US patients only
|
In-segment (+5mm from the stent edges) MLD
|
13 months - US patients only
|
In-segment late loss
Time Frame: 13 months - US patients only
|
In-segment (+5mm from the stent edges) late loss
|
13 months - US patients only
|
Proximal late loss
Time Frame: 13 months - US patients only
|
Proximal late loss (+5 mm from proximal stent edge)
|
13 months - US patients only
|
Distal late loss
Time Frame: 13 months - US patients only
|
Distal late loss (+5 mm from proximal stent edge)
|
13 months - US patients only
|
In-stent and in-segment Binary Restenosis
Time Frame: 13 months - US patients only
|
In-stent and in-segment Binary Restenosis
|
13 months - US patients only
|
OCT-determined inner layer percent neointimal hyperplasia volume
Time Frame: 13 months - US patients only
|
OCT-determined inner layer percent neointimal hyperplasia volume
|
13 months - US patients only
|
In-stent MLA
Time Frame: 13 months - US patients only
|
In-stent MLA
|
13 months - US patients only
|
In-segment minimum lumen area (MLA)
Time Frame: 13 months - US patients only
|
In-segment minimum lumen area (MLA)
|
13 months - US patients only
|
Minimal stent area (MSA)
Time Frame: 13 months - US patients only
|
Minimal stent area (MSA)
|
13 months - US patients only
|
Stent expansion
Time Frame: 13 months - US patients only
|
Stent expansion
|
13 months - US patients only
|
Edge dissection
Time Frame: 13 months - US patients only
|
Edge dissection
|
13 months - US patients only
|
% NIH at the MLA
Time Frame: 13 months - US patients only
|
% NIH at the MLA
|
13 months - US patients only
|
% Area stenosis at the MLA
Time Frame: 13 months - US patients only
|
% Area stenosis at the MLA
|
13 months - US patients only
|
Luminal gain (MLA post-procedure - MLA pre-procedure)
Time Frame: 13 months - US patients only
|
Luminal gain (MLA post-procedure - MLA pre-procedure)
|
13 months - US patients only
|
In-stent late loss MLA
Time Frame: 13 months - US patients only
|
In-stent late loss MLA
|
13 months - US patients only
|
In-segment (+5 mm from the stent edges) late loss (MLA).
Time Frame: 13 months - US patients only
|
In-segment (+5 mm from the stent edges) late loss (MLA).
|
13 months - US patients only
|
Proximal late loss (+5 mm from proximal stent edge) (MLA)
Time Frame: 13 months - US patients only
|
Proximal late loss (+5 mm from proximal stent edge) (MLA)
|
13 months - US patients only
|
Distal late loss (+5 mm from distal stent edge) (MLA)
Time Frame: 13 months - US patients only
|
Distal late loss (+5 mm from distal stent edge) (MLA)
|
13 months - US patients only
|
Intraluminal mass at least 0.2 mm beyond the luminal edge of a strut
Time Frame: 13 months - US patients only
|
Intraluminal mass at least 0.2 mm beyond the luminal edge of a strut (Intraluminal mass attached to the vessel is defined as an irregularly shaped structure in contact with the luminal contour, a free intraluminal mass is defined as an isolated structure in the lumen without contact to the vessel wall)
|
13 months - US patients only
|
Malapposition
Time Frame: 13 months - US patients only
|
Malapposition (stent struts clearly separated from the vessel wall (lumen border/plaque surface) without tissue behind the struts with a distance from the adjacent intima of ≥0.2 mm not associated with any side branch)
|
13 months - US patients only
|
% Covered strut
Time Frame: 13 months - US patients only
|
% Covered strut (NIH thickness of >0 μm).
|
13 months - US patients only
|
% Healthy covered strut
Time Frame: 13 months - US patients only
|
% Healthy covered strut (NIH thickness≥40 μm).
|
13 months - US patients only
|
Peri-strut low intensity area
Time Frame: 13 months - US patients only
|
Peri-strut low intensity area (peri-strut region of homogeneous lower intensity observed without signal attenuation).
|
13 months - US patients only
|
Healing score
Time Frame: 13 months - US patients only
|
Healing score (defined as % intraluminal mass [=intraluminal mass volume/stent volume] ×4 + % malposed and uncovered struts ×3 + (% uncovered struts alone ×2 + % malposed struts alone ×1) at 13 months.
|
13 months - US patients only
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IoNIR-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on IoNIR Ridaforolimus-Eluting Coronary Stent System
-
Medinol Ltd.RecruitingIonMAN Trial- First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (IonMAN)Cardiovascular Diseases | Coronary Disease | Non-ST Elevated Myocardial Infarction | Coronary StenosisIsrael, Brazil
-
Medinol Ltd.Completedde Novo or Restenosis LesionsJapan
-
Medinol Ltd.Completed
-
Medinol Ltd.CompletedMyocardial Ischemia | Cardiovascular Diseases | Coronary Disease | Coronary StenosisIsrael
-
ReFlow Medical, Inc.Not yet recruiting
-
Shanghai Jiao Tong University School of MedicineCompletedCoronary Artery Disease | DiabetesChina
-
Atrium Medical CorporationTerminatedCoronary Artery DiseaseNew Zealand
-
Cook Group IncorporatedTerminatedCoronary Artery DiseaseGermany